Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma [Phase 3]
Phase III trial assessing SyB L-0501 with Rituximab in recurrent/relapsed diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma [Phase 4]
A Phase 4 clinical trial update evaluating selinexor in combination with R-GemOx as second-line therapy for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]
Phase II study evaluating oral panobinostat (LBH589) in combination with rituximab for diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Genotype-guided Treatment in DLBCL [Phase 3]
Phase 3 clinical trial updating genotype-guided treatment for Diffuse Large B Cell Lymphoma (DLBCL) is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma [Phase 1, Phase 2]
Clinical trial updates the combination of obinutuzumab with lenalidomide for relapsed/refractory follicular and aggressive B-cell lymphomas,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial update for TC-110 T cells in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia (comple…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Umbilical Cord Blood NK cells with Rituximab, high-dose chemotherapy, and stem cell transplant in recurrent or refr…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial assessing survival and autonomy in elderly relapsed diffuse large B-cell lymphoma patients treated with Rituximab plus chemoth…
-
CLINICAL_TRIALS trial_result · 2023-02-03Clinical Trial Update: Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL [Phase 2]
Phase 2 trial evaluating orelabrutinib in combination with a R-CHOP-like regimen for newly diagnosed untreated non-GCB diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) [Phase 2]
A Phase 2 trial update for lisocabtagene maraleucel (JCAR017) as second-line therapy in non-Hodgkin lymphoma has been completed with results…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL [Phase 2]
Phase II study update of FIL in elderly frail patients with Diffuse Large B-Cell Lymphoma (DLBCL) completed.
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL [Phase 2]
Phase 2 trial results for pembrolizumab after autologous stem cell transplant in Hodgkin lymphoma, diffuse large B-cell lymphoma, and periph…
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: Reduced Chemotherapy in Low Risk DLBCL [Phase 4]
Phase 4 clinical trial update evaluating reduced chemotherapy in patients with diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluated lenalidomide and rituximab in combination with chemotherapy for newly diagnosed diffuse large…
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating venetoclax in combination with R-ICE chemotherapy for relapsed/refractory diffuse large B-cell lymphoma is active…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 study assessing safety, pharmacokinetics, and efficacy of oral CC-223 in advanced solid tumors, non-Hodgkin lymphoma, or multiple …
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed/refractory follicular lym…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating R-CHOP plus metformin in diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating Rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma (DLBCL), including people with HIV, h…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Treatment for Advanced B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial completed for treatment of advanced B-cell lymphoma, including diffuse large B-cell lymphoma and Burkitt's lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating mitoxantrone with clofarabine for recurrent non-Hodgkin lymphoma or acute leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mitoxantrone hydrochloride liposome plus rituximab and lenalidomide (M+R2) in relapsed/refractory diffus…
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas [Phase 2]
Phase II trial evaluating alemtuzumab with DA-EPOCH-R in relapsed or refractory Hodgkin lymphoma and diffuse large B-cell lymphoma has compl…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…